Table 1.
Patient characteristics of the CGCI and LLMPP cohorts
| CGCI | LLMPP | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients n (%) | GCB n (%) | Non-GCB n (%) | p -val | Patients n (%) | GCB n (%) | Non-GCB n (%) | p -val | ||
| All n (%) | 92 (100) | 51 (55) | 41 (45) | 233 (100) | 107 (46) | 126 (54) | |||
| Gender | Female | 31 (34) | 19 (37) | 12 (29) | 0.51 | 99 (42) | 49 (46) | 50 (40) | 0.356 |
| Male | 61 (66) | 32 (63) | 29 (71) | 134 (58) | 58 (54) | 76 (60) | |||
| Age | <60 | 39 (42) | 20 (39) | 19 (46) | 0.78 | 109 (47) | 56 (52) | 53 (42) | 0.264 |
| 60–65 | 15 (16) | 9 (18) | 6 (15) | 29 (12) | 13 (12) | 16 (13) | |||
| >60 | 38 42) | 22 (43) | 16 (39) | 95 (41) | 38 (36) | 57 (45) | 0.109 | ||
| Stage | I−II | 44 (48) | 28 (55) | 16 (39) | 0.15 | 105 (45) | 54 (52) | 51 (42) | |
| III−IV | 48 (52) | 23 (45) | 25 (61) | 121 (55) | 49 (48) | 72 (58) | |||
| IPI | 0–2 | 62 (67) | 35 (69) | 27 (66) | 0.83 | 112 (48) | 56 (76) | 56 (62) | 0.091 |
| 3–5 | 30 (33) | 16 (31) | 14 (34) | 52 (52) | 18 (24) | 34 (38) | |||
| IMPA1 | Low | 69 (75) | 42 (82) | 27 (66) | 0.09 | 218 (94) | 104 (97) | 114 (90) | 0.058 |
| High | 13 (25) | 9 (18) | 14 (34) | 15 (6) | 3 (3) | 12 (10) | |||
| MAPK1 | Low | 27 (29) | 12 (24) | 15 (37) | 0.25 | 50 (21) | 27 (25) | 23 (18) | 0.205 |
| High | 65 (71) | 39 (76) | 26 (63) | 183 (79) | 80 (75) | 103 (82) | |||
| PIP5K1A | Low | 78 (85) | 46 (90) | 32 (78) | 0.15 | 223 (96) | 104 (97) | 119 (94) | 0.35 |
| High | 14 (15) | 5 (10) | 9 (22) | 10 (4) | 3 (3) | 7 (6) | |||
| CACNG3 | Low | 77 (84) | 46 (90) | 31 (76) | 0.09 | 131 (56) | 63 (59) | 68 (54) | 0.508 |
| High | 15 (16) | 5 (10) | 10 (24) | 102 (44) | 44 (41) | 58 (46) | |||
| RASGRP3 | Low | 82 (89) | 47 (92) | 35 (85) | 0.33 | 183 (79) | 77 (72) | 106 (84) | 0.026 |
| High | 10 (11) | 4 (8) | 6 (15) | 50 (21) | 30 (28) | 20 (16) | |||
| SYK | Low | 81 (88) | 44 (86) | 37 (90) | 0.75 | 219 (94) | 98 (92) | 121 (96) | 0.176 |
| High | 11 (12) | 7 (14) | 4 (10) | 14 (6) | 9 (8) | 5 (4) | |||